The European Medicines Agency granted marketing authorization for tislelizumab and retifanlimab for the treatment of non–small cell lung cancer and Merkel cell carcinoma, respectively.
In this cohort study, researchers identified 6146 patients from 17 registries of the SEER Program who had been diagnosed with a first primary cutaneous Merkel cell carcinoma between 2000 and 2018.